Primary central nervous system lymphoma Journal Article


Authors: Clarke, J. L.; Deangelis, L. M.
Article Title: Primary central nervous system lymphoma
Abstract: Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma restricted to the nervous system, affecting the brain, cerebrospinal fluid, eyes, or spinal cord. It occurs with increased frequency in immunocompromised patients, particularly those with human immunodeficiency virus infection. Diagnosis is usually established by stereotactic biopsy as resection is not an essential component of therapy. Initial treatment should include chemotherapy, particularly regimens containing high-dose methotrexate, which is the single most important drug for the treatment of PCNSL. Complete response rates can approach 80% but, even with vigorous therapy, relapse is common. Median survival is approximately 3-4 years with high-dose methotrexate-based regimens with or without cranial irradiation. Combined modality treatment is associated with a high rate of neurotoxicity, with older age and long follow-up as the primary risk factors. Current approaches have focused on reducing relapse rates and improving disease control while minimizing neurotoxicity. These include: (1) reducing the dose of cranial irradiation in patients who have achieved a complete response to chemotherapy; (2) intensifying chemotherapy using autologous stem cell rescue regimens; and (3) intensifying standard chemotherapy alone. © 2012 Elsevier B.V.
Journal Title: Handbook of Clinical Neurology
Volume: 105
ISSN: 0072-9752
Publisher: Elsevier B.V.  
Date Published: 2012-01-01
Start Page: 517
End Page: 527
Language: English
DOI: 10.1016/b978-0-444-53502-3.00006-9
PROVIDER: scopus
PUBMED: 22230516
DOI/URL:
Notes: Chapter 34 of "Neuro-Oncology, Part II" (ISBN: 9780444535023) -- "Export Date: 1 March 2012" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jennifer L Clarke
    11 Clarke